A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
about
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsPancreatic neuroendocrine tumors: the basics, the gray zone, and the target.A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid MalignanciesRecent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical developmentA Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.BEZ235: When Promising Science Meets Clinical RealitymTOR function and therapeutic targeting in breast cancer.Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.mTORC1 and mTORC2 in cancer and the tumor microenvironment.Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.Effective combinatorial immunotherapy for castration-resistant prostate cancerPhase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.The PI3K Pathway in Human Disease.Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication.Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma.Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapymTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related DiseasesA systematic review and meta-analysis of gastrointestinal events associated with nonoperative therapies for neuroendocrine tumors
P2860
Q26740374-52328C09-9FA2-4013-8EBB-31ACF40DA791Q33672117-6A1A926B-9226-4660-858B-56891EC96812Q33735754-2097E16C-7E11-4C62-A440-A49CB1E7FDBBQ33776641-FFD12644-80E8-4A4D-BC0B-46D9D2A0339AQ37091157-2709334B-7A0C-45B1-9DA5-8617E815585EQ37242369-83519EA0-FDA8-4FA4-B49D-0C01471CCF37Q37743486-078B45DE-85B6-4A74-94DE-1A88B5A8A559Q38786234-1772D23B-6A42-423F-8CBB-1626206BB4CEQ38982579-889BC22C-ADE9-4AC6-A201-3C37FB55DE9CQ41559421-EDFFBEB7-5B09-455B-B905-EA16FAC7348EQ41716558-3CF8FD84-DC12-4C4D-B17F-8D2744EB08EEQ46392522-E37CD6CB-8C41-454A-9822-5714D3520AA8Q46546002-C225792E-40BF-40C1-975A-42A720AA01E4Q47955211-B97D8701-4E3D-4032-9CD4-B9A9ABC99FC0Q48123819-9F74680E-3CFC-4BB6-90C3-4E86AB2CEE92Q52687754-188CE121-C46A-4B68-8452-4F7652A13089Q52717288-968A3757-2DE1-4471-8F0B-318E07CA38ADQ57072192-1772F803-91E3-49C7-BBAA-717438C91413Q58795101-485A11B5-FD08-42D2-95B1-B1749E917232Q59135219-0873EA98-6074-4F78-95AD-655E57E346A3
P2860
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A Phase II Study of BEZ235 in ...... reatic Neuroendocrine Tumours.
@en
A Phase II Study of BEZ235 in ...... reatic Neuroendocrine Tumours.
@nl
type
label
A Phase II Study of BEZ235 in ...... reatic Neuroendocrine Tumours.
@en
A Phase II Study of BEZ235 in ...... reatic Neuroendocrine Tumours.
@nl
prefLabel
A Phase II Study of BEZ235 in ...... reatic Neuroendocrine Tumours.
@en
A Phase II Study of BEZ235 in ...... reatic Neuroendocrine Tumours.
@nl
P2093
P2860
P1433
P1476
A Phase II Study of BEZ235 in ...... reatic Neuroendocrine Tumours.
@en
P2093
Alexandre Teulé
Chris Verslype
Cristian Massacesi
Debarshi Dey
Eric Baudin
Harald Lahner
Jaume Capdevila
Lorenzo Antonuzzo
Manisha Shah
Markus Raderer
P2860
P304
P407
P577
2016-02-01T00:00:00Z